223 related articles for article (PubMed ID: 22872679)
1. Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1.
Ashkenazi A; Viard M; Unger L; Blumenthal R; Shai Y
FASEB J; 2012 Nov; 26(11):4628-36. PubMed ID: 22872679
[TBL] [Abstract][Full Text] [Related]
2. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
[TBL] [Abstract][Full Text] [Related]
3. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.
Heil ML; Decker JM; Sfakianos JN; Shaw GM; Hunter E; Derdeyn CA
J Virol; 2004 Jul; 78(14):7582-9. PubMed ID: 15220433
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Qiu Z; Xiong S; He Y
J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
[TBL] [Abstract][Full Text] [Related]
5. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
[TBL] [Abstract][Full Text] [Related]
6. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
7. Resistance to enfuvirtide, the first HIV fusion inhibitor.
Greenberg ML; Cammack N
J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
[TBL] [Abstract][Full Text] [Related]
8. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
9. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.
He Y; Cheng J; Lu H; Li J; Hu J; Qi Z; Liu Z; Jiang S; Dai Q
Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16332-7. PubMed ID: 18852475
[TBL] [Abstract][Full Text] [Related]
10. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Cai L; Gochin M; Liu K
Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
[TBL] [Abstract][Full Text] [Related]
11. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
[TBL] [Abstract][Full Text] [Related]
12. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
Pan C; Cai L; Lu H; Qi Z; Jiang S
J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
[TBL] [Abstract][Full Text] [Related]
13. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
[TBL] [Abstract][Full Text] [Related]
14. Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.
Baatz F; Nijhuis M; Lemaire M; Riedijk M; Wensing AM; Servais JY; van Ham PM; Hoepelman AI; Koopmans PP; Sprenger HG; Devaux C; Schmit JC; Perez Bercoff D
PLoS One; 2011; 6(7):e21535. PubMed ID: 21760896
[TBL] [Abstract][Full Text] [Related]
15. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
Champagne K; Shishido A; Root MJ
J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
[TBL] [Abstract][Full Text] [Related]
16. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S
Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358
[TBL] [Abstract][Full Text] [Related]
17. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
18. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
Pan C; Lu H; Qi Z; Jiang S
AIDS; 2009 Mar; 23(5):639-41. PubMed ID: 19242316
[TBL] [Abstract][Full Text] [Related]
19. Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency.
Dwyer JJ; Wilson KL; Martin K; Seedorff JE; Hasan A; Medinas RJ; Davison DK; Feese MD; Richter HT; Kim H; Matthews TJ; Delmedico MK
Protein Sci; 2008 Apr; 17(4):633-43. PubMed ID: 18359857
[TBL] [Abstract][Full Text] [Related]
20. Are fusion inhibitors active against all HIV variants?
Poveda E; Rodes B; Toro C; Soriano V
AIDS Res Hum Retroviruses; 2004 Mar; 20(3):347-8. PubMed ID: 15117459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
